Biomarin Pharmaceutical Inc. BMRN

NAS: BMRN | ISIN: US09061G1013   14/07/2025
58,23 USD (+0,22%)
(+0,22%)   14/07/2025

12 mei 2025 · BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings · Persbericht

1 mei 2025 · BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance · Persbericht

17 april 2025 · BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET · Persbericht

2 april 2025 · BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria · Persbericht

20 maart 2025 · BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting · Persbericht

4 september 2024 · BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance · Persbericht

4 september 2024 · BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time · Persbericht

29 augustus 2024 · BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY · Persbericht

21 augustus 2024 · BioMarin Announces New R&D and Business Development Leadership · Persbericht

19 augustus 2024 · BioMarin to Host 2024 Investor Day on September 4th in New York · Persbericht

5 augustus 2024 · BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance · Persbericht

5 augustus 2024 · BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy · Persbericht

24 juli 2024 · U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease · Persbericht

23 juli 2024 · BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET · Persbericht

17 juni 2024 · BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health · Persbericht

8 juni 2024 · KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 · Persbericht

7 juni 2024 · BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress · Persbericht

8 mei 2024 · BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV · Persbericht

4 mei 2024 · New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting · Persbericht

24 april 2024 · BioMarin Reports Record Financial Results for the First Quarter 2024 · Persbericht

Mijn selecties